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Personalized medicine is an emerging field that promises to bring 
radical changes in health care. It can be defined as “a medical model 
that uses molecular profiling technologies for tailoring the right 
therapeutic option for the right person at the right time and being 
potentially able to determine the predisposition to disease at the 
population level and to deliver timely and stratified prevention” 
(1–3). The sequencing of the human genome together with the 
development and implementation of new high-throughput tech-
nologies (so-called omics) have greatly enhanced not only our 
knowledge on human cancer biology but have also opened up the 
ways to breakthroughs bringing much closer the possibility to a 
personalized patient treatment. Although all these omics have been 
widely used at experimental level to identify new targets, to define 
the impact of alteration on activity of classical anticancer agents or 
target-oriented drugs, and to characterize the toxicological profile 
of new drugs leading to a dramatic improvement in our knowledge 
on the molecular basis of cancer, we are still far from having clari-
fied the entire picture. There is therefore the need to support studies 
aimed at defining the mechanisms of cancer biology as this will lead 
to the rational discovery of omics-based markers and the develop-
ment of more reliable preclinical disease models. Several omics 
platforms, particularly those for the analysis of nucleic acids, are 
ready for clinical application but others, such as proteomics, epig-
enomics, cell functional analysis, etc, require further development 
before they can contribute to large-scale clinical translational stud-
ies that aim at identifying and validating biomarkers and biosigna-
tures. Breast cancer represents the oncologic field in which 
application of these omics has been most widely applied. Several 
translational clinical trials have introduced genomic and transcrip-
tomic studies with the aim of selecting patients more likely 
to respond to a given therapy (4–7). For example, it has been 
suggested that gene expression signatures of breast carcinomas may 
not only lead to new classifications of tumor subgroups but also 
carry prognostic and predictive information. Gene profiling studies 
have consistently showed that estrogen receptor (ER)–negative and 
ER-positive breast cancers are different biological diseases and that 
each of them can be further divided in subgroups with distinct 
disease-free and overall survivals and thus different oncological 
approaches are needed. This new molecular classification of breast 
cancer has been reproduced across different laboratories, patient 
populations, and array platforms (8).
We will first summarize the different omics technologies that 
have been developed and then discuss how these have been applied 
in the context of the primary setting of breast cancer.
Epigenomics
Epigenetic alterations are those alterations found in DNA not 
affecting its primary structure, which ends up with aberrant 
transcription. DNA methylation, remodeling, and histone modifi-
cations represent the different level of epigenetic alterations found 
in human cells all interacting one to each other. In breast cancer, 
several genes are found methylated, and a temptative signature of 
genes methylated has been found associated with prognosis (9,10). 
Epigenetic silencing in breast cancer is in fact not only associated with 
tumor initiation and progression but also in the development of drug 
resistance. Genome-wide methylation analysis allows the detection of 
whole methylation as well as specific gene methylation pattern in 
clinical specimen. The development of bisulfite conversion–based 
technique greatly facilitated the detection of methylated genes, and 
the combination with real-time polymerase chain reaction made 
possible a quantitation of gene methylation. Together with DNA 
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methylation analysis, histone modifications are gaining importance 
in epigenetics (11,12). Histone cores undergo a series of posttransla-
tional modifications (methylation, acetylation, ubiquitination, 
sumoylation), which are important for chromatin structure. The 
analysis of histone modifications in clinical specimens is now possible 
with a relatively high-throughput analysis represented by Chromatin 
Immunoprecipitation-on-chip and recently by Chip-SAGE (9).
Metabolomics
Metabolomics refers to the assessment of metabolic potential of an 
individual (through pharmacogenomic and detailed P450s analysis), 
and it is extremely useful in predicting toxicity of certain actively 
metabolized drugs, depending on the low- or high-metabolizing 
capacities of the patient. More challenging is the global metabolomic 
analysis, which is the detection of small molecules in organic fluids 
and tissues, often representing end product of cellular processes. 
The increasing availability of methods in nuclear magnetic reso-
nance and mass spectrometry able to detect with high accuracy the 
levels of small molecules allows the detection of these end products, 
which reflect the sum of the response to a biological treatment or 
to the uncontrolled growth characteristics of the tumor (13–15). 
Metabolomics could be regarded as a potential way to classify 
tumors and to predict response to treatment. Even the metabolomic-
based classification has been applied in breast cancer, no direct applica-
tion in patient’s selection in clinical trials has yet emerged (16–18).
Proteomics
Highly sensitive and specific techniques, which are able to detect low 
levels of proteins in virtually all clinical specimens, have been devel-
oped. Technologies such as matrix-assisted laser desorption/ioniza-
tion-time-of-flight mass spectrometry, surface-enhanced laser 
desorption/ionization-mass spectrometry, liquid chromatography-
mass spectrometry, isotope-coded affinity tags, and isobaric tags for 
relative and absolute quantitation are now quite accessible to different 
laboratories, although the complexity of sample preparation and 
analysis remains high, relative to genomic and transcriptomic analysis 
(19). Nevertheless, proteomics analyses have been used to try to 
identify biomarkers for diagnosis and response assessment (20–24). 
Although in clinical trials in breast cancer, protein analysis (ie, ER, 
progesterone receptor, HER2) is used to stratify patients as luminal 
A or B. For HER2 subtype, triple negative (25), a more comprehen-
sive proteomic analysis is warranted. Different kinases are expressed 
in different clinical subsets of breast cancer. Bianchini et al. (26) 
recently, using omics approaches assessed kinase expression patterns 
in different clinical subtypes of breast cancer, evaluated the prognos-
tic and predictive values of kinase metagenes; they identified that 
kinases regulating mitosis and immune functions convey distinct 
prognostic information that varies by clinical subtype.
Indeed, the development of complex networks of protein inter-
actions is likely to be more useful in the definition of new strategies 
in clinical trials, and in the near future, these techniques will be 
incorporated in clinical designs. In addition, the assessment of 
the functional status of a protein can be more informative, and this 
can be done analyzing the posttranslational protein modifications 
(such as phosphorylation, acetylation, and methylation). Furthermore, 
the analysis of specific “subproteomic” blocks, like the analysis of all 
the secreted proteins, the secretome could be an additional tool to 
determine which signaling pathway is potentially driving for the 
tumor and increase the chance of a more selective therapy (27,28).
Statistomics in Clinical Trials With 
Biological Targets
The Bayesian approach is an ideal statistical method in designing 
and analyzing clinical trials based on biological targets (29,30) as it 
allows: 1) the use of all the available evidence combining many 
sources of information (including “expert opinions”) and borrowing 
strength across patients within the same trial and across trials; 2) the 
guarantee of a higher degree of flexibility; in a Bayesian trial, the 
sample size need not be chosen in advance, but the go and stop deci-
sion can be made at any time as more evidence becomes available; 
3) for the provision of methods to calculate predictive probabilities 
regarding future events (like the probability that a certain subject 
will respond to a new therapy) that do not depend upon unknown 
parameters. These characteristics have implications for analysis as 
well as design. Typical goals in the Bayesian approach include faster 
learning via more effective designs of trials and more efficient drug 
development along with better treatment of patients who partici-
pate in the trial.
Omics in Primary Setting of Breast Cancer
The development of molecular profiling technologies to assess DNA, 
RNA, protein, and metabolites provides the potential to tailor medi-
cal care both at the tumor and patient levels. Indeed, the personalized 
approach offers the real opportunity to increase the therapeutic effi-
cacy by targeting the genomic abnormalities driving tumors while 
decreasing the possible side effects of the therapy due to altered 
metabolism depending on the patients’ genetic background (Figure 
1). The development and use of Herceptin, designed to target HER2-
positive tumors, is an excellent example of advances in tailoring 
breast cancer treatment to biology. In both the pivotal trastuzumab 
as single-agent and in combination with chemotherapy trials, 
responses were seen only in patients where the “target” +3 overex-
pression of the HER2 receptor protein detected by immunohisto-
chemistry, or amplification of its gene detected by fluorescence in 
situ hybridization, was present (31–33).
When the activity of trastuzumab was analyzed in the entire 
breast cancer population, no major responses were seen. If based 
only on the results in this unselected population, an excellent drug 
would have been discarded as not worthy of further development.
The HER2 pathway story led the omics approaches to be largely 
used in breast cancer studies, reducing the distance between the 
laboratory and the clinical department, till merging them to put the 
discoveries coming from the bench to the bedside as a tool to a bet-
ter understanding of tumor behavior. In the era of targeted therapy, 
breast oncologists started using “translation research” terminology 
more often in their approach to treatment (eg, gene profile, fluores-
cence in situ hybridization, mutations/sequencing, etc.) till individu-
ating different steps of the translation research spectrum in their 
clinical practice (Table 1) as follows: 
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 • Step point 1: translation of basic research into clinical application.
 • Step point 2: clinical application to evidence-based practice 
guidelines.
 
The two major applications of translational research are the 
identification of predictive factors and of new therapeutic targets. 
The majority of breast cancer patients are offered some type of 
systemic therapy. However, traditional anticancer therapy is 
empirical, and it extrapolates to an individual patient the conclu-
sions of studies carried out in wide populations, with a high likeli-
hood that many patients are treated to benefit a few. In general, 
neither side effects nor absolute benefit can be reliably predicted 
for an individual patient. Therefore, the main challenge for the 
oncology community has become the identification of predictive 
factors that will help select the optimal therapeutic strategy 
for each individual patient. This better selection of patients and 
treatment-tailoring is essential to avoid both overtreatment, with 
its potential for severe complications, and undertreatment with its 
deleterious consequences for patient survival.
In this context, the primary setting of breast cancer offers a unique 
emerging possibility for the both the rapid validation of biomarkers, 
as the anatomical accessibility of the breast provides the potential 
for serial biopsies to investigate molecular changes during treatment; 
as well as the possibility to identify new effective treatment strategies 
minimizing treatment-related side effects, to study the mechanism 
Figure 1. Schematic highthroughput approach for the selection the best therapeutic option for cancer patients. Ideally, the integrated approach will 
take into account the different aspects of tumor (at the DNA, RNA, and protein levels) and patient (pharmacogenomics), and, with the aid of statistic 
analysis tools, will generate an integrated tumor/patient signature specific for each patient.
Table 1. The step-points of the translation research in oncology
The translation research workflow in oncology
Translation research  
spectrum  Setting Examples
Step point 1 Discovery of new Phase I and II clinical trial HER2 and tumor aggressiveness;  
 mechanisms of action—trastuzumab
Step point 2 Health application to  
 evidence-based medicine
Phase III and IV clinical trial;  
 observational studies
HER2 expression in breast cancer and  
 trastuzumab/population benefits
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of action of a drug, and to develop clinically applicable prognostic 
and predictive biomarkers in an attempt to individualize therapy.
Recently, a study based on the predictive role of MammaPrint in 
relation to pathological complete response after neoadjuvant treat-
ment was published. The study shows that tumors with a poor 
70-gene signature are more likely to achieve a pathological complete 
response (pCR), whereas tumors with a good prognosis signature 
are not. This finding has several important clinical implications: 1) a 
real application of genomics in a clinical setting; 2) the 70-gene profile 
could help in selecting patients for adjuvant chemotherapy, whereby 
chemotherapy is frequently withheld for tumors with a good progno-
sis signature (lower risk of relapse and tumor less sensitive to chemo-
therapy); 3) we also believe that the stratification of subjects according 
to the 70-gene profile could be helpful in controlled trials investigat-
ing the effectiveness of new drugs or new combinations of drugs.
In this setting, the opportunity to develop a more personalized 
treatment in an accelerated time frame is another great advantage. 
In fact, traditional drug development processes utilize adjuvant 
trials requiring long follow-ups, many thousands of patients, and 
many years to go from laboratory bench to patient bedside.
Table 2 reports a number of trials where omics have been 
applied. The I-SPY trial (Investigation of Serial Studies to Predict 
Your Therapeutic Response with Imaging And moLecular analysis) 
had the goal to identify indicators of response to neoadjuvant 
chemotherapy predicting survival in women with high-risk (stage 
II–III) breast cancer. This trial was designed to connect clinical, 
laboratory, and bioinformatics investigators with a novel model 
for the evaluation of neoadjuvant chemotherapy in locally 
advanced breast cancer, trying to bring together data from mul-
tiple molecular biomarkers with magnetic resonance imaging. 
In I-SPY 1, chemotherapy was administered before surgery and 
biomarkers were compared with tumor response assessed by mag-
netic resonance imaging, pathological residual disease at the time 
of surgery, and a 3-year disease-free survival. This trial demon-
strates that a collaborating group of investigators could effectively 
integrate biomarkers and imaging by agreeing on standards for 
data collection, biomarker assessment, and magnetic resonance 
imaging. The robust infrastructure built up during I-SPY 1 was 
instrumental for the setting up of the ongoing I-SPY 2 trial 
launched in 2010 (I-SPY 2: An Adaptive Breast Cancer Trial 
Design in the Setting of Neoadjuvant Chemotherapy). This trial 
will use biomarkers to identify women who might benefit from 
investigational new drugs given along with standard neoadjuvant 
chemotherapy (chemotherapy given before surgery) with pacli-
taxel, doxorubicin, and cyclophosphamide. The trial will enroll 
women who have early-stage breast cancer and a high risk of 
recurrence, as determined by ER status, HER2 status, and the 
MammaPrint test. There are four key transformative concepts 
in the I-SPY 2 trial that deserve comment: 
 1) It has an adaptive trial design. The patients’ assignment to a 
specific investigational drug will change/adapt through the trial. 
The information of how patients respond to their treatment is 
based on the biological profile of their tumor and will deter-
mine the assignment of subsequent patients with the same 
tumor profile to the available treatment (Bayesian methods of 
adaptive randomization). 
 2) It has early endpoints. Tumor tissue will be collected at surgery 
to assess whether the patient has pathological complete response. 
This is the primary trial endpoint, but patients will also be fol-
lowed for disease-free and overall survival for up to 10 years.
 3) It has rapid/simultaneous multiple drug evaluation. The trial 
will concurrently test three to five investigational drugs from 
different companies against a single control group.
 4) The testing of the concept of personalized medicine is based on 
the molecular tools that have been developed in the last decade. 
Patients will be randomized to specific treatment arms based on 
the US Food and Drug Administration–approved biomarker 
tests that define the biological profile of the patients tumor (ER 
status, HER2 status, and the MammaPrint test). In addition, 
newer promising biomarker tests can potentially be collected 
and could be correlated with tumor response.
This study has been designed to move promising new drugs (up 
to 12) into phase III clinical trials more quickly and cost-effectively 
than traditional phase II studies. The adaptive design approach 
provides a model for rapid assessment of novel phase II drugs and 
identification of effective drugs and drug combinations so as to 
determine which breast cancer subtypes will benefit. Specifically, 
learning will occur as the trial proceeds, and use of information 
from each patient will inform subsequent treatment assignments. 
The real possibility of learning what works within months rather 
than years makes the information available from this trial transfor-
mational for patients with breast cancer.
Conclusions
Proof-of-concept projects demonstrating the feasibility of bringing 
early returns from the omics revolution to the health care should be 
considered. Exploratory and high-risk projects that aim to develop 
novel omics technologies for application in the clinical setting for 
the discovery of biomarkers or signatures are to be encouraged. 
Indeed, the ultimate impact of omics technologies on improving 
the delivery of personalized medicine will depend on demonstrat-
ing its cost-effective utility in daily practice. The cost of generating 
large-scale prospective biobanks/trials with high-quality outcome 
data is enormous. The successful integration of omics-based 
personalized medicine into clinical practice does not only require 
the demonstration of its clinical utility and cost-effectiveness but 
also the development of processes so that the relevant information 
is available to the correct health practitioner at the appropriate 
time. In addition, and to further advance personalized medicine, the 
National Health System should promote evidence-based multidis-
ciplinary training of omics researchers, clinician scientists, quantita-
tive scientists, clinical care and pharmas, biotechs, and health-care 
policy makers with the aim to introduce validated and cost-effective 
omics technologies, including clinical bioinformatics and statistics, 
into health-care systems.
Finally, as a cautionary and provocative note, we should not 
forget that if the theory of the existence of the cancer stem cell 
is correct, we should rethink all our concepts of determining 
“peripheral” tumor characteristics and focus on finding the 
Achilles’ heel of the tumor, the cancer stem cell, which needs to 
be targeted to successfully eradicate the tumor. In these times in 
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Table 2. Breast cancer trials in the neoadjuvant setting with omics application*
Type of trial Decription Findings References
Molecular  
 genomic
I-SPY: multicenter clinical trial designed to evaluate  
 the impact of chemotherapy before surgery on  
 patients with locally advanced breast cancer.  
 Biological markers as predictors of pCR and  
 survival were considered.
The molecular profiles of locally advanced breast  
 cancer tumors predicted the response of the  
 tumors to chemotherapy drugs given in  





I-SPY 2: it was designed to efficiently screen  
 multiple novel drugs. It includes an “adaptive  
 design” in which drugs are assessed over the  
 course of months—rather than decades—and the 
 information used in real time to direct the course of  
 a trial. It also will test the qualification of biomarkers  
 to help accelerate the path to the identification and  
 availability of successful tailored treatment options  
 for women with locally advanced breast cancer.
Ongoing (4)
Phase II/III randomized study of neoadjuvant  
 therapy of exemestane vs letrozole vs  
 anastrozole in postmenopausal women  
 with ER-positive to determine whether  
 patients who have a high Ki67 value (>10%)  
 after 2 weeks of neoadjuvant aromatase  
 inhibitors treatment have a higher than expected  
 pathological response rate to neoadjuvant  
 chemotherapy (20%) than would be typically  
 observed for postmenopausal patients with  
 unselected ER-positive rich tumors.
Ongoing (34)
The result of this study would potentially indicate  
 that an early assessment of proliferation could  
 be a useful approach to the identification of a  
 chemotherapy-sensitive subgroup of ER-positive  
 tumors.
Molecular signatures of neoadjuvant endocrine  
 therapy for breast cancer: Characteristics of  
 response or intrinsic resistance. Untreated  
 postmenopausal patients with ER-positive  
 breast cancers were treated for 4 months in  
 a neoadjuvant setting with the aromatase  
 inhibitor exemestane alone or with tamoxifen.
Matched pre- and posttreatment tumor samples from  
 the same patient were analyzed by gene expression  
 profiling and were correlated with response to  
 treatment. Genes associated with response to  
 endocrine therapy were identified that may  
 distinguish ER-positive hormone-responsive  
 breast cancers from ER-positive tumors that  
 exhibit intrinsic or de novo resistance.
Expression profiles differentiate between  
 breast cancers clinically responsive or  
 resistant to letrozole.
Expression profiles on high-density microarray chips  
 were related to clinical responses assessed from  
 tumor volume measurements after 3 months of  
 treatment in 52 patients with breast cancer.
Evaluation of a 30-gene paclitaxel, fluorouracil,  
 doxorubicin, and cyclosphosphamide (T/FAC)  
 chemotherapy response predictor in a  
 multicenter randomized trial in breast cancer
The 30-gene predictor (DLDA-30) could identify  
 patients with greater than average sensitivity to  
 (T/FAC) chemotherapy.
(7)
Epigenomic Identification of DNA methylation biomarker to  
 discriminate patients with locally advanced  
 breast cancer who may benefit from  
 neoadjuvant doxorubicin treatment.
Methylation of two out 14 genes analyzed (ABCB1  
 and GSRP1) were associated with improved  
 survival, whereas methylation of FOXC1 seemed to  
 be a protective factor against tumor invasiveness
(35)
Proteomic Identification of markers of response in neoadjuvant  
 paclitaxel/radiation therapy by histology-directed  
 matrix-assisted desorption/ionization mass  
 spectrometry (MALDI-MS).
Identification of differentially expressed peptides in  
 tumor biopsies from pCR and non-pCR (nonresponder)  
 patients. Gene expression arrays were also used to  
 identify differentially expressed genes.
(36)
Evaluation of changes in serum protein  
 levels during neoadjuvant chemotherapy  
 in HER2-positive breast cancer.
Using an LC-MALDI-TOF/MS procedure changes in serum 
 protein levels of patients treated with neoadjuvant  
 chemotherapy were found, and these changes partially 
 differ between patients highly sensitive to chemotherapy 
 and patients less responsive.
(37)
Protein expression changes after neoadjuvant  
 use of aromatase inhbitors in primary breast  
 cancer.
By a proteomic approach (mass spectrometry) changes  
 in protein expression (both up- and down-regulation)  
 protein were found after aromatase inhibitor. Among  
 these proteins, heat shock protein 70 demonstrated  
 the most significant positive correlation with the  
 clinical response of the patients.
(38)
* ER = estrogen receptor; pCR = pathological complete response.
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which we are moving to a comprehensive analysis of tumor com-
plexity as a whole, we should perhaps have a look back to a more 
reductionistic system.
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